Nvidia(US:NVDA) 量子位·2025-06-29 07:43Core Viewpoint - Nvidia's venture arm NVentures has invested in TerraPower, a nuclear energy company founded by Bill Gates, marking a significant entry into the nuclear sector by Jensen Huang [1][4]. Group 1: Investment and Financing - TerraPower has secured $650 million in funding to construct its first commercial nuclear power plant, the Natrium reactor project, located in Wyoming, USA [2]. - The financing round also included investments from South Korea's Hyundai and Bill Gates himself [4]. Group 2: Technology and Capacity - The Natrium reactor will generate 345 megawatts of power, with a peak output of 500 megawatts, sufficient to power approximately 400,000 homes [3]. - The reactor employs sodium-cooled fast reactor (SFR) technology, which uses liquid sodium as a coolant, enhancing safety and simplifying design compared to traditional water-cooled reactors [13]. - The Natrium system integrates a gigawatt-level molten salt energy storage system, allowing for flexible power output adjustments to meet grid demands [15][17]. Group 3: Future Developments - TerraPower is also developing molten chloride fast reactor (MCFR) technology, which operates at higher temperatures, potentially increasing efficiency and providing process heat for industrial applications [19]. - Both SFR and MCFR technologies are part of the fourth generation of nuclear energy systems, which include various innovative approaches to nuclear power generation [21]. Group 4: Industry Trends - The surge in nuclear investment is driven by the increasing electricity demand from AI data centers, with notable figures like Sam Altman actively investing in nuclear energy companies [37][38]. - Other tech giants, such as Amazon and Google, are also making significant investments in nuclear energy, indicating a broader trend within the industry [46]. Group 5: Additional Applications - TerraPower is not solely focused on nuclear power; it is also exploring the use of nuclear technology for cancer treatment, specifically through the development of Ac-225 for targeted alpha therapy [48][49].